At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1,307 enrolled
Drug / intervention
Mirabegron +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder.
In Brief
A Phase 2 clinical trial evaluating Mirabegron, Solifenacin succinate, and 1 other intervention for Urologic Diseases and 4 related conditions. Completed, enrolled 1,307 participants across 133 sites in 20 countries.
Detailed Summary
The purpose of this study is to examine how well two medicines in combination (solifenacin succinate and mirabegron) work in the treatment of bladder problems over a 12-week period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrologic Diseases, Urinary Bladder Diseases, Urological Manifestations, Signs and Symptoms, Urinary Bladder, Overactive
CountriesBelarus, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedApr 2011
Primary CompletionJun 2012
TodayJul 2026
First PostedApr 21, 2011
Enrollment StartMar 29, 2011
Primary CompletionJun 28, 2012
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 15.2 years ago
Interventions
Mirabegrondrug
oral
Solifenacin succinatedrug
oral
Placebodrug
oral